MedTrace Logo

Aspirin and Clopidogrel Resistance Study

NCT01039480 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 82

Last updated 2012-02-09

No results posted yet for this study

Summary

Resistance to antiplatelet drugs (aspirin, clopidogrel) is a recognized phenomenon with a prevalence from 17% to 35%. Resistance as detected by in vitro tests such as Multiple Electrode Aggregometry (MEA) has been shown to predict clinical therapy failure. Resistance can be caused by clinical, cellular and pharmacogenetic factors. Non compliance is suspected to be an important contributing factor. In this study, compliance will be assured with an electronical compliance monitoring system. Factors to non response will be identified to find plausible explanations when in vitro platelet aggregation inhibition is insufficient despite assured compliance. This study will help to disclose the relationship between compliance, biomarker and clinical outcome as well as to quantify the impact of non compliance to the resistance phenomenon as measured by MEA.

Conditions

  • Drug Resistance

Sponsors & Collaborators

  • University Hospital, Basel, Switzerland

    lead OTHER

Principal Investigators

  • Kurt E Hersberger, PhD · Pharmaceutical Care Research Group, Departement of Pharmacy, University Basel

  • Michel Romanens, MD · Kardiologische Praxis, Olten/SO

  • Dimitrios Tsakiris, MD · Hemostaseology Lab, University Hospital Basel

  • Philipp N Walter, MSc · Pharmaceutical Care Research Group, Department of Pharmacy, University of Basel

Eligibility

Min Age
45 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-05-31
Primary Completion
2011-06-30
Completion
2011-10-31

Countries

  • Switzerland

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01039480 on ClinicalTrials.gov